New Research on PCA3 Presented at the 2013 European Association of Urology (EAU) Congress

New Research on PCA3 Presented at the 2013 European Association of Urology 
(EAU) Congress 
PCA3 has an Established Place in the Diagnosis of Prostate Cancer 
QUEBEC CITY, March 21, 2013 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR) is 
pleased to report that Dr. Harry Rittenhouse spoke about the clinical utility 
of the urinary marker PCA3 during the International Conference on Prostate 
Cancer Prevention 2013 with Consensus Conference on Chemoprevention of 
Prostate Cancer held during the 28(th) annual European Association of Urology 
(EAU) congress held in Milan from March 15-19th. 
One of the goals of this day-long special session during the EAU congress was 
to discuss current management approaches to prostate cancer screening and 
hopefully come up with some consensus statements in early detection and 
prognostic biomarkers to predict high grade disease and the most appropriate 
clinical preventions. One of the session chairmen, Professor Powel Brown of 
M.D. Anderson Cancer Center in Houston, Texas, shared his hopes to see a 
strong message on the use of biomarkers for prognostic stratification of 
prostate cancer into low and high risk disease. For Dr. Jack A. Schalken, 
Professor of experimental urology at the Radboud University Nijmegen Medical 
Center (The Netherlands), there is no doubt that "PCA3 has an established 
place in the diagnosis of prostate cancer and is now also considered for 
follow-up use in chemoprevention studies". 
In a separate thematic session where prostate cancer experts from both sides 
of the Atlantic discussed current work on candidate tumor markers for prostate 
cancer and the prospects for these biomarkers to serve as possible 
replacements for PSA-based diagnosis, presentations were given by Dr. Jack 
Groskopf (Hologic Gen-Probe, USA) who discussed urinary markers PCA3 and 
TMPRSS2-ERG, and Dr. Monique Roobol (Erasmus University Medical Center, The 
Netherlands) who provided insights on studies that examine reducing 
unnecessary biopsies for suspicion of prostate cancer. 
The Annual EAU Congress is Europe's largest urology event and serves as a 
platform for the international urological community to share the latest and 
the most relevant knowledge with medical experts practicing across the board. 
About DiagnoCure 
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and 
commercializes high-value cancer diagnostic tests that increase clinician and 
patient confidence in making critical treatment decisions. In 2008, the 
Corporation launched a colorectal cancer staging test through its U.S. CLIA 
laboratory. Previstage(TM)GCC is currently available for licensing. The 
Corporation has granted a worldwide exclusive license agreement to Gen-Probe, 
now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as 
Hologic Gen-Probe, for the development and commercialization of a prostate 
cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic 
Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and 
is approved for commercialization in Canada and the United States. For more 
information, visit www.diagnocure.com. 
Forward‐looking statements 
This release contains forward‐looking statements that involve known and 
unknown risks, uncertainties and assumptions that may cause actual results to 
differ materially from those expected. By their very nature, forward‐looking 
statements are based on expectations and hypotheses and also involve risks and 
uncertainties, known and unknown, many of which are beyond DiagnoCure's 
control. As a result, investors are cautioned not to place undue reliance on 
these forward‐looking statements. The forward-looking statements regarding 
the outcome of research and development projects, clinical studies and future 
revenues are based on management expectations. In addition, the reader is 
referred to the applicable general risks and uncertainties described in 
DiagnoCure's most recent Annual Information Form under the heading "Risk 
Factors". DiagnoCure undertakes no obligation to publicly update or revise any 
forward‐looking statements contained herein unless required by the 
applicable securities laws and regulations. 
Investors DiagnoCure Inc. Chantal Miklosi Chief Financial Officer 
(418) 527-6100 communications@diagnocure.com 
Media DiagnoCure Inc. Geneviève Couture Coordinator, Administration and 
Communications (418) 527-6100 communications@diagnocure.com  
SOURCE: DiagnoCure inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/21/c7159.html 
CO: DiagnoCure inc.
ST: Quebec
NI: MTC HEA HEA  
-0- Mar/21/2013 20:00 GMT